europrotection in Aneurysmal Subarachnoid Hemorrhage - from Laboratory to Clinical Practice
Phase 2
Withdrawn
- Conditions
- 10007963subarachnoid hemorrhage
- Registration Number
- NL-OMON29768
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
aneurysmal subarachnoid hemorrhage
Exclusion Criteria
- non-aneurysmal causes of subarachnoid hemorrhage
- pregnancy
- use of interferon
- a history of hypersensitivity to natural or recombinant interferon
- severe depression and/or suicidal ideation
- decompensated liver disease.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>- relatie between studymedicatie and complicatiions </p><br>
- Secondary Outcome Measures
Name Time Method <p>- serum TNF alfa<br /><br>- the occurrence of DCI within three months after onset of SAH and poor outcome<br /><br>after three months. DCI is defined as the occurrence of a new spontaneous<br /><br>hypodense lesion as revealed by a CT scan compatible with clinical features of<br /><br>DCI<br /><br>(gradually developed focal deficits, decreased level of consciousness, or<br /><br>both). Three months after the SAH we assess functional outcome with the<br /><br>modified Rankin scale, a 6-point handicap scale that focuses on restrictions in<br /><br>lifestyle, by means of a telephone interview.</p><br>